PMID- 36505287
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221221
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 14
IP  - 11
DP  - 2022
TI  - Effect of mesalazine combined with probiotics on inflammation and immune function 
      of patients with inflammatory bowel disease.
PG  - 8234-8242
AB  - OBJECTIVE: To determine the effects of mesalazine combined with probiotics on 
      inflammation and immune function of patients with inflammatory bowel disease 
      (IBD). METHODS: In this retrospective study, a total of 116 patients with IBD 
      treated in Renmin Hospital of Wuhan University from September 2018 to September 
      2021 were enrolled and divided into a control group (n=55, treated with 
      mesalazine alone) and a research group (n=61, treated with mesalazine combined 
      with probiotics) according to the treatment regimen. The two groups were compared 
      in the levels of inflammatory factors, immune factors, adverse reactions, 
      clinical efficacy and improvement of patients' disease condition before and after 
      treatment. Logistic regression was used to analyze the independent risk factors 
      of infection in patients with IBD at 6 months after admission. RESULTS: The 
      research group showed a significantly higher the total effective rate than the 
      control group (P<0.05), and there was no notable difference between the two 
      groups in the incidence of adverse reactions (P>0.05). In addition, compared with 
      the control group, the research group showed significantly lower levels of 
      immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), Tumor 
      necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), C-reactive protein (CRP), and 
      had significantly lower scores of clinical activity index (CAI) and endoscopic 
      activity index (EAI) after treatment (all P<0.05). Higher IgG, IgM, IL-6, CRP and 
      EAI levels at admission were independent risk factors for infection in patients 
      with IBD. CONCLUSION: Mesalazine combined with probiotics can substantially 
      improve the disease condition of patients with IBD, improve their immune ability 
      and reduce their inflammation level, with a good safety profile.
CI  - AJTR Copyright (c) 2022.
FAU - Tan, Feifei
AU  - Tan F
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University Wuhan 430060, 
      Hubei, China.
AD  - Department of Key Laboratory of Hubei Province for Digestive System Disease, 
      Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China.
FAU - Deng, Yinzhi
AU  - Deng Y
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University Wuhan 430060, 
      Hubei, China.
AD  - Department of Key Laboratory of Hubei Province for Digestive System Disease, 
      Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China.
FAU - Guo, Jinkun
AU  - Guo J
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University Wuhan 430060, 
      Hubei, China.
AD  - Department of Key Laboratory of Hubei Province for Digestive System Disease, 
      Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China.
FAU - Zhou, Zhongyin
AU  - Zhou Z
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University Wuhan 430060, 
      Hubei, China.
AD  - Department of Key Laboratory of Hubei Province for Digestive System Disease, 
      Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China.
FAU - Luo, Hesheng
AU  - Luo H
AD  - Department of Gastroenterology, Renmin Hospital of Wuhan University Wuhan 430060, 
      Hubei, China.
AD  - Department of Key Laboratory of Hubei Province for Digestive System Disease, 
      Renmin Hospital of Wuhan University Wuhan 430060, Hubei, China.
LA  - eng
PT  - Journal Article
DEP - 20221115
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC9730058
OTO - NOTNLM
OT  - Mesalazine
OT  - immune function
OT  - inflammatory bowel disease
OT  - inflammatory function
OT  - probiotics
COIS- None.
EDAT- 2022/12/13 06:00
MHDA- 2022/12/13 06:01
PMCR- 2022/11/15
CRDT- 2022/12/12 10:56
PHST- 2022/06/12 00:00 [received]
PHST- 2022/08/17 00:00 [accepted]
PHST- 2022/12/12 10:56 [entrez]
PHST- 2022/12/13 06:00 [pubmed]
PHST- 2022/12/13 06:01 [medline]
PHST- 2022/11/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2022 Nov 15;14(11):8234-8242. eCollection 2022.